Sarepta (SRPT) knew about the death of a limb-girdle disease patient yesterday on its gene therapy when it announced the restructuring and layoffs, but did not disclose it, Stat’s Adam Feuerstein reported last night via X.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta patient death could bring greater scrutiny, says William Blair
- Morning Movers: 3M and Charles Schwab tick higher following quarterly results
- Video: Netflix slips after earnings, Sarepta sinks after patient death in study
- Sarepta price target lowered to $41 from $45 at Oppenheimer
- Sarepta tells Bloomberg limb-girdle patient died of liver failure in study